Formycon AG (0W4N.L)

EUR 53.2

(0.95%)

EBITDA Summary of Formycon AG

  • Formycon AG's latest annual EBITDA in 2023 was 81.05 Million EUR , up 109.2% from previous year.
  • Formycon AG's latest quarterly EBITDA in 2024 Q2 was -17.51 Million EUR , down 0.0% from previous quarter.
  • Formycon AG reported an annual EBITDA of 51.53 Million EUR in 2022, down -29.88% from previous year.
  • Formycon AG reported an annual EBITDA of -12.42 Million EUR in 2021, down -153.25% from previous year.
  • Formycon AG reported a quarterly EBITDA of -5.93 Million EUR for 2023 Q4, down 0.0% from previous quarter.
  • Formycon AG reported a quarterly EBITDA of N/A for 2023 FY, up 109.2% from previous quarter.

Annual EBITDA Chart of Formycon AG (2023 - 2009)

Historical Annual EBITDA of Formycon AG (2023 - 2009)

Year EBITDA EBITDA Growth
2023 81.05 Million EUR 109.2%
2022 51.53 Million EUR -29.88%
2021 -12.42 Million EUR -153.25%
2020 -5.9 Million EUR -254.92%
2019 -1.36 Million EUR -116.94%
2018 8.02 Million EUR 1124.41%
2017 -751.5 Thousand EUR 76.58%
2016 -3.34 Million EUR -309.07%
2015 1.59 Million EUR -17.65%
2014 1.94 Million EUR 129.28%
2013 -6.63 Million EUR -248.76%
2012 -1.97 Million EUR -55.01%
2011 -1.22 Million EUR -22.08%
2010 -1 Million EUR -446.7%
2009 -183.85 Thousand EUR 0.0%

Peer EBITDA Comparison of Formycon AG

Name EBITDA EBITDA Difference
Boiron SA 80.67 Million EUR -0.464%
Laboratorios Farmaceuticos Rovi, S.A. 238.01 Million EUR 65.947%
Vetoquinol SA 104.58 Million EUR 22.497%
Valneva SE -64.51 Million EUR 225.63%
AB Science S.A. -9.28 Million EUR 973.322%
Nanobiotix S.A. -34.01 Million EUR 338.258%
PHAXIAM Therapeutics S.A. -22.93 Million EUR 453.48%
Vivoryon Therapeutics N.V. -28.35 Million EUR 385.871%
BioSenic S.A. -6.79 Million EUR 1292.657%
ABIVAX Société Anonyme -133.2 Million EUR 160.847%